Comparative Pharmacology
Head-to-head clinical analysis: BETAINE versus CHOLYBAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAINE versus CHOLYBAR.
BETAINE vs CHOLYBAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine, via betaine-homocysteine methyltransferase (BHMT). This reduces homocysteine levels, particularly in homocystinuria.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, preventing their reabsorption and promoting cholesterol catabolism.
Oral: 3 g twice daily (6 g/day total). Administer with food.
10 g (one packet) orally three times daily, mixed with 4-6 ounces of water or other liquid.
None Documented
None Documented
Terminal elimination half-life is approximately 14-16 hours in adults with normal renal function; may be prolonged in renal impairment.
Not applicable systemically because Cholybar is not absorbed. The local gastrointestinal transit half-life is approximately 2-4 hours, but clinical effects persist based on bile acid depletion.
Renal: approximately 80% as betaine and its metabolite dimethylglycine; fecal: <5%; biliary: negligible.
Primarily hepatic; Cholybar is not absorbed systemically, acting locally in the gut. Excretion is fecal (>99%) as the resin and bound bile acids. Renal excretion is negligible (<1%).
Category C
Category C
Nutritional Supplement
Nutritional Supplement